StreetInsider.com News Articles

Seaport Therapeutics shares Phase 1 PK data for GlyphAgo at ECNP

Fri, 09 Oct 2026 13:00:20 -0400

Seaport Therapeutics (Nasdaq: SPTX), a clinical-stage neuropsychiatric drug developer and founded entity of PureTech Health (LSE: PRTC), presented Phase 1 pharmacokinetic data for its drug candidate GlyphAgo™ (SPT-320) at the 39th European College of Neuropsychopharmacology Congress in Munich, Germany.

The presentation, described by the company as the first scientific presentation of data from the GlyphAgo Phase 1 program, included results from a multi-part trial enrolling 174 healthy volunteers. The data showed a statistically significant 6.8-fold increase in bioavailability of agomelatine compared to unmodified agomelatine, along with a 10-fold reduction in pharmacokinetic variability.

The trial's single- and multiple-ascending dose portions showed dose-dependent increases

PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

Fri, 09 Oct 2026 13:00:00 -0400

BOSTON--(BUSINESS WIRE)-- PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced the presentation of Phase 1 clinical data for GlyphAgo™ (SPT-320 or Glyph Agomelatine) at the 39th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 10-13, 2026, in Munich, Germany. The poster represents the first scientific presentation of data from the GlyphAgo Phase 1 program and provides detailed pharmacokinetic (PK) analyses supporting previously reported topline results and reinforcing

PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

Fri, 09 Oct 2026 13:00:00 -0400

Seaport Therapeutics shares Phase 1 PK data for GlyphAgo at ECNP

Fri, 09 Oct 2026 07:00:29 -0400

Seaport Therapeutics (Nasdaq: SPTX) presented Phase 1 pharmacokinetic (PK) data for its drug candidate GlyphAgo at the 39th European College of Neuropsychopharmacology Congress in Munich, Germany, running October 10-13, 2026.

The presentation marked the first detailed scientific disclosure of PK data from the GlyphAgo Phase 1 program. According to the company, GlyphAgo demonstrated a statistically significant 6.8-fold increase in agomelatine bioavailability compared to unmodified agomelatine, along with a 10-fold reduction in PK variability.

The completed Phase 1 trial enrolled 174 healthy volunteers and evaluated safety, tolerability, and pharmacokinetics. Data from the multiple-ascending dose portion showed dose-dependent increases in agomelatine exposure with no

Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

Fri, 09 Oct 2026 07:00:00 -0400

First scientific presentation of detailed PK data demonstrates dose-dependent increases in agomelatine exposure, no food effect, and no accumulation of exposure over seven days of dosing

Detailed data reinforces previously reported topline results demonstrating that GlyphAgo achieved a statistically significant 6.8-fold increase in agomelatine bioavailability and substantially lower (10-fold) PK variability compared to unmodified agomelatine

Agomelatine levels comparable to those seen with efficacious doses of the unmodified drug were achieved at substantially lower doses, intended to reduce hepatic exposure and the potential for liver enzyme elevations

BOSTON--(BUSINESS WIRE)-- Seaport Therapeutics, Inc. (Nasdaq: SPTX)

Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

Fri, 09 Oct 2026 07:00:00 -0400

First scientific presentation of detailed PK data demonstrates dose-dependent increases in agomelatine exposure, no food effect, and no accumulation of exposure over seven days of dosing

BOSTON--(BUSINESS WIRE)-- Seaport Therapeutics, Inc. (Nasdaq: SPTX)

H.C. Wainwright Reiterates Buy Rating on Seaport Therapeutics (SPTX)

Thu, 08 Oct 2026 07:04:59 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $50.00 price target on Seaport Therapeutics (NASDAQ: SPTX).

The analyst commented: "Yesterday, Seaport Therapeutics announced that the first patient has been dosed in a Phase 2a trial in Australia evaluating GlyphAgo (SPT-320 or Glyph Agomelatine), in adults with generalized anxiety disorder (GAD) and sleep disturbance. GlyphAgo is a novel, “Glyphed” oral prodrug of agomelatine, a clinically validated MT1/MT2 melatonin receptor agonist and serotonin 2C (5-HT2C) receptor antagonist. Agomelatine has demonstrated statistically significant separation from placebo in four third-party placebo-controlled studies in GAD. In the six-week Phase 2a clinical trial, patients with

Seaport Therapeutics doses first patient in anxiety disorder trial

Wed, 07 Oct 2026 13:00:31 -0400

Seaport Therapeutics (Nasdaq: SPTX), a founded entity of PureTech Health (LSE: PRTC), announced that the first patient has been dosed in a Phase 2a clinical trial in Australia evaluating GlyphAgo™ (SPT-320) in adults with generalized anxiety disorder (GAD) and sleep disturbance.

The six-week, double-blind trial is testing two dose levels of GlyphAgo — 16 mg/day and 32 mg/day — and is designed to establish proof-of-pharmacology by evaluating the drug's effects on sleep, measured through patient-reported outcomes and EEG-based sleep architecture assessments. Additional endpoints include anxiety severity, overall illness severity, and safety and pharmacokinetics. Topline data are expected in early 2028.

GlyphAgo is

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance

Wed, 07 Oct 2026 13:00:00 -0400

BOSTON--(BUSINESS WIRE)-- PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced that the first patient has been dosed in a Phase 2a clinical trial in Australia evaluating GlyphAgo™ (SPT-320 or Glyph Agomelatine) in adults with generalized anxiety disorder (“GAD”) and sleep disturbance. The six-week trial is designed to establish proof-of-pharmacology by evaluating the effects of GlyphAgo on sleep. Seaport expects to report topline data from the trial in early

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance

Wed, 07 Oct 2026 13:00:00 -0400

BOSTON--(BUSINESS WIRE)-- PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced that the first patient has been dosed in a Phase 2a clinical trial in Australia evaluating GlyphAgo™ (SPT-320 or Glyph Agomelatine) in adults with generalized anxiety disorder (“GAD”) and sleep disturbance. The six-week trial is designed to establish proof-of-pharmacology by evaluating the effects of GlyphAgo on sleep. Seaport expects to report topline data from the trial in early

Seaport Therapeutics doses first patient in GlyphAgo anxiety trial

Wed, 07 Oct 2026 07:00:18 -0400

Seaport Therapeutics (Nasdaq: SPTX) announced that the first patient has been dosed in a Phase 2a clinical trial in Australia evaluating GlyphAgo (SPT-320), an oral prodrug of agomelatine, in adults with generalized anxiety disorder (GAD) and sleep disturbance.

The six-week, double-blind trial randomizes patients to one of two dose levels: 16 mg/day or 32 mg/day of GlyphAgo, containing approximately 5 mg or 10 mg of agomelatine, respectively. Primary endpoints include patient-reported sleep outcomes measured by the Insomnia Severity Index and EEG-based sleep architecture assessments. Secondary endpoints include anxiety severity via the Hamilton Anxiety Scale and overall illness severity. Topline data are

Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance

Wed, 07 Oct 2026 07:00:00 -0400

Trial is designed to demonstrate proof-of-pharmacology by evaluating the effects of GlyphAgo on sleep and anxiety symptoms in patients with generalized anxiety disorder

In Phase 1, GlyphAgo demonstrated a statistically significant 6.8-fold increase in bioavailability compared to unmodified agomelatine, achieving therapeutically relevant exposures of agomelatine at doses designed to reduce liver exposure

Topline data from the Phase 2a clinical trial are expected in early 2028

Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance

Wed, 07 Oct 2026 07:00:00 -0400

Trial is designed to demonstrate proof-of-pharmacology by evaluating the effects of GlyphAgo on sleep and anxiety symptoms in patients with generalized anxiety disorder

Topline data from the Phase 2a clinical trial are expected in early 2028

Raymond James Starts Seaport Therapeutics (SPTX) at Strong Buy

Fri, 25 Sep 2026 06:07:05 -0400

(Updated - September 25, 2026 6:07 AM EDT)

Raymond James analyst Tiago Fauth initiates coverage on Seaport Therapeutics (NASDAQ: SPTX) with a Strong Buy rating and a price target of $46.00.

The analyst comments "We are initiating coverage of Seaport Therapeutics (SPTX) at Strong Buy with a $46 target price. We see SPTX as a GlyphAllo story in 2027, GlyphAgo story in 2028, and a Glyph2BLSD story in 2029. ● Catalyst #1: GlyphAllo’s Phase 2b BUOY-1 readout in 1H27. This is the fundamental nearterm catalyst, and the key debate here is whether Sage’s zuranolone history represents mechanistic validation or mechanistic failure. We

Raymond James Starts Seaport Therapeutics (SPTX) at Strong Buy

Fri, 25 Sep 2026 06:07:05 -0400

(Updated - September 25, 2026 6:07 AM EDT)

Raymond James analyst Tiago Fauth initiates coverage on Seaport Therapeutics (NASDAQ: SPTX) with a Strong Buy rating and a price target of $46.00.

Raymond James Starts Seaport Therapeutics (SPTX) at Strong Buy

Fri, 25 Sep 2026 06:07:05 -0400

(Updated - September 25, 2026 6:07 AM EDT)

Raymond James analyst Tiago Fauth initiates coverage on Seaport Therapeutics (NASDAQ: SPTX) with a Strong Buy rating and a price target of $46.00.

Raymond James Starts Seaport Therapeutics (SPTX) at Strong Buy

Fri, 25 Sep 2026 06:07:05 -0400

(Updated - September 25, 2026 6:07 AM EDT)

Raymond James analyst Tiago Fauth initiates coverage on Seaport Therapeutics (NASDAQ: SPTX) with a Strong Buy rating and a price target of $46.00.

Seaport Therapeutics to Participate in September Investor Conferences

Mon, 14 Sep 2026 07:00:00 -0400

BOSTON--(BUSINESS WIRE)-- Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in a series of additional upcoming investor conferences in September, including a company presentation and panel discussion featuring Co-Founder and Chief Executive Officer, Daphne Zohar, at the Goldman Sachs Life Sciences Symposium on September 15, 2026.

Seaport management will also participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit and in one-on-one investor meetings

Seaport Therapeutics to Participate in September Investor Conferences

Mon, 14 Sep 2026 07:00:00 -0400

Seaport management will also participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit and in one-on-one investor meetings

Seaport Therapeutics reports GlyphAllo shows no driving impairment

Wed, 09 Sep 2026 07:01:54 -0400

Seaport Therapeutics (Nasdaq: SPTX) announced positive topline results from a Phase 1 driving simulation trial of GlyphAllo (SPT-300), an oral prodrug of allopregnanolone, in healthy volunteers, according to a company statement.

The trial met its primary endpoint, showing that evening dosing of GlyphAllo at 375 mg did not impair next-morning driving performance compared to placebo on Day 5 following multiple-day dosing. A key secondary endpoint was also met, showing that a single 250 mg dose did not impair next-morning driving performance compared to placebo on Day 2.

The trial included a 7.5 mg dose of zopiclone as a positive control. Zopiclone produced

Seaport Therapeutics reports GlyphAllo shows no driving impairment

Wed, 09 Sep 2026 07:01:54 -0400

The trial included a 7.5 mg dose of zopiclone as a positive control. Zopiclone produced

Jones Trading Starts Seaport Therapeutics (SPTX) at Buy

Tue, 25 Aug 2026 16:17:38 -0400

(Updated - August 25, 2026 4:17 PM EDT)

Jones Trading analyst Justin Walsh initiates coverage on Seaport Therapeutics (NASDAQ: SPTX) with a Buy rating and a price target of $32.00.

The analyst comments "We are initiating coverage of Seaport Therapeutics (SPTX) with a Buy rating and $32 price target. Seaport is a clinical-stage biotechnology company developing novel treatments for depression, anxiety, and other neuropsychiatric disorders using its proprietary Glyph lymphatic-targeting prodrug platform. The company's strategy is to apply Glyph to clinically validated molecules whose therapeutic potential has historically been constrained by poor bioavailability, extensive first-pass metabolism, pharmacokinetic variability, tolerability concerns, or intellectual-property

Jones Trading Starts Seaport Therapeutics (SPTX) at Buy

Tue, 25 Aug 2026 16:17:38 -0400

(Updated - August 25, 2026 4:17 PM EDT)

Jones Trading analyst Justin Walsh initiates coverage on Seaport Therapeutics (NASDAQ: SPTX) with a Buy rating and a price target of $32.00.

H.C. Wainwright Reiterates Buy Rating on Seaport Therapeutics (SPTX)

Thu, 20 Aug 2026 06:58:28 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $50.00 price target on Seaport Therapeutics (NASDAQ: SPTX).

The analyst commented: "We recently spoke with Seaport Therapeutics management about various developments across the spectrum of neuropsychiatry, particularly pertaining to the competitive landscape in major depression and the re-emergence of psychedelics. In particular, we feel that the top-line data from MapLight Therapeutics' (MPLT; Buy) ML-007C-MA candidate has somewhat reduced long-term competitive pressure for Seaport, particularly with respect to GlyphAllo, while the augmented profiles of various psychedelic candidates in late-stage development may raise investor awareness of Seaport's Glyph2BLSD candidate. Glyph2BLSD is a non-hallucinogenic

Form SCHEDULE 13G Seaport Therapeutics, Filed by: PureTech LYT, Inc.

Fri, 14 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26931618.html